Influence of tunneling on electron screening in low energy nuclear reactions in laboratories

Using a semiclassical mean field theory, we show that the screening potential exhibits a characteristic radial variation in the tunneling region in sharp contrast to the assumption of the constant shift in all previous works. Also, we show that the explicit treatment of the tunneling region gives a larger screening energy than that in the conventional approach, which studies the time evolution only in the classical region and estimates the screening energy from the screening potential at the external classical turning point. This modification becomes important if the electronic state is not a single adiabatic state at the external turning point either by pre-tunneling transitions of the electronic state or by the symmetry of the system even if there is no essential change with the electronic state in the tunneling region.Comment: 3 figure

Slow relaxation due to optimization and restructuring: Solution on a hierarchical lattice

Motivated by the large strain shear of loose granular materials we introduced a model which consists of consecutive optimization and restructuring steps leading to a self organization of a density field. The extensive connections to other models of statistical phyics are discussed. We investigate our model on a hierarchical lattice which allows an exact asymptotic renormalization treatment. A surprisingly close analogy is observed between the simulation results on the regular and the hierarchical lattices. The dynamics is characterized by the breakdown of ergodicity, by unusual system size effects in the development of the average density as well as by the age distribution, the latter showing multifractal properties.Comment: 11 pages, 7 figures revtex, submitted to PRE see also: cond-mat/020920

Search for the Rare Decay KL --> pi0 ee

The KTeV/E799 experiment at Fermilab has searched for the rare kaon decay KL--> pi0ee. This mode is expected to have a significant CP violating component. The measurement of its branching ratio could support the Standard Model or could indicate the existence of new physics. This letter reports new results from the 1999-2000 data set. One event is observed with an expected background at 0.99 +/- 0.35 events. We set a limit on the branching ratio of 3.5 x 10^(-10) at the 90% confidence level. Combining the results with the dataset taken in 1997 yields the final KTeV result: BR(KL --> pi0 ee) < 2.8 x 10^(-10) at 90% CL.Comment: 4 pages, three figure

Environmental monitoring : phase 5 final report (April 2019 - March 2020)

This report presents the results and interpretation for Phase 5 of an integrated environmental monitoring programme that is being undertaken around two proposed shale gas sites in England – Preston New Road, Lancashire and Kirby Misperton, North Yorkshire. The report should be read in conjunction with previous reports freely available through the project website1 . These provide additional background to the project, presentation of earlier results and the rationale for establishment of the different elements of the monitoring programme

Measurements Of The Decay Kl → E+e-μ+μ-

Several 132 KL → e+e- μ+ μ- events were observed from the 1997 and 1999 runs of the KTeV experiments, with an estimated background of 0.8 events. In the first measurement of the parameter α using this decay mode, it was found that α=-1.59±0.37. No evidence was found for CP-violating contributions to the KLγ*γ* interaction.9014141801/1141801/5Wolfenstein, L., (1983) Phys. Rev. Lett., 51, p. 1945Belanger, G., Geng, C.Q., (1991) Phys. Rev. D, 43, p. 140Buras, A.J., Fleischer, R., (1998) Advanced Ser. Direct. High Energy Phys., 15, p. 65Uy, Z.E.S., (1991) Phys. Rev. D, 43, p. 802D'Ambrosio, G., Isidori, G., Portolès, J., (1998) Phys. Lett. B, 423, p. 385Alavi-Harati, A., (2001) Phys. Rev. Lett., 87, p. 71801. , KTeV CollaborationAlavi-Harati, A., (2001) Phys. Rev. Lett., 86, p. 5425. , KTeV CollaborationUy, Z.E.S., (2002) Eur. Phys. J. C, 23, p. 113Alavi-Harati, A., (2001) Phys. Rev. Lett., 87, p. 111802. , KTeV CollaborationHamm, J.C., (2002), Ph.D. thesis, The University of Arizona(Fermilab Report No. fERMILAB-THESIS-2002-09)Alavi-Harati, A., (1999) Phys. Rev. Lett., 83, p. 922. , KTeV CollaborationAlavi-Harati, A., (2000) Phys. Rev. D, 61, p. 072006. , KTeV CollaborationBrown, C., (1996) Nucl. Instrum. Methods Phys. Res., Sect. A, 369, p. 248Quinn, G.B., (2000), Ph.D. thesis, The University of ChicagoBarker, A.R., Huang, H., Toale, P.A., Engle, J., hep-ph/0210174Bergström, L., Massó, E., Singer, P., (1983) Phys. Lett., 131 B, p. 229Fanti, V., (1999) Phys. Lett. B, 458, p. 553. , NA48 Collaboratio

Energy loss due to defect formation from 206Pb recoils in SuperCDMS germanium detectors

The Super Cryogenic Dark Matter Search experiment at the Soudan Underground Laboratory studied energy loss associated with defect formation in germanium crystals at mK temperatures using in situ 210Pb sources. We examine the spectrum of 206Pb nuclear recoils near its expected 103 keV endpoint energy and determine an energy loss of (6:08 ± 0:18)%, which we attribute to defect formation. From this result and using TRIM simulations, we extract the first experimentally determined average displacement threshold energy of 19.7+0.6−0.5 eV for germanium. This has implications for the analysis thresholds of future germanium-based dark matter searches

Psychology and aggression

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/68264/2/10.1177_002200275900300301.pd

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulations. We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and, to explore the antitussive mechanism of PA101, patients with chronic idiopathic cough (CIC) were also studied. Methods This pilot, proof-of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chronic cough and a parallel study of similar design in patients with CIC. Participants with IPF and chronic cough recruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a computer-generated randomisation schedule) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation for 2 weeks, followed by a 2 week washout, and then crossed over to the other arm. Study participants, investigators, study staff, and the sponsor were masked to group assignment until all participants had completed the study. The primary efficacy endpoint was change from baseline in objective daytime cough frequency (from 24 h acoustic recording, Leicester Cough Monitor). The primary efficacy analysis included all participants who received at least one dose of study drug and had at least one post-baseline efficacy measurement. Safety analysis included all those who took at least one dose of study drug. In the second cohort, participants with CIC were randomly assigned in a study across four centres with similar design and endpoints. The study was registered with ClinicalTrials.gov (NCT02412020) and the EU Clinical Trials Register (EudraCT Number 2014-004025-40) and both cohorts are closed to new participants. Findings Between Feb 13, 2015, and Feb 2, 2016, 24 participants with IPF were randomly assigned to treatment groups. 28 participants with CIC were enrolled during the same period and 27 received study treatment. In patients with IPF, PA101 reduced daytime cough frequency by 31·1% at day 14 compared with placebo; daytime cough frequency decreased from a mean 55 (SD 55) coughs per h at baseline to 39 (29) coughs per h at day 14 following treatment with PA101, versus 51 (37) coughs per h at baseline to 52 (40) cough per h following placebo treatment (ratio of least-squares [LS] means 0·67, 95% CI 0·48–0·94, p=0·0241). By contrast, no treatment benefit for PA101 was observed in the CIC cohort; mean reduction of daytime cough frequency at day 14 for PA101 adjusted for placebo was 6·2% (ratio of LS means 1·27, 0·78–2·06, p=0·31). PA101 was well tolerated in both cohorts. The incidence of adverse events was similar between PA101 and placebo treatments, most adverse events were mild in severity, and no severe adverse events or serious adverse events were reported. Interpretation This study suggests that the mechanism of cough in IPF might be disease specific. Inhaled PA101 could be a treatment option for chronic cough in patients with IPF and warrants further investigation

Measurements of differential production cross sections for a Z boson in association with jets in pp collisions at root s=8 TeV

Peer reviewe